Novo Nordisk, Europe’s most valuable company, has announced a collaboration agreement with Valo Health to discover and develop innovative treatments for cardiometabolic diseases. This partnership will leverage the power of human data and artificial intelligence to tackle conditions such as heart attack, stroke, and diabetes.
Valo Health specializes in drug discovery and development, utilizing cutting-edge technologies like patient data analysis and AI. They also employ a human tissue modeling platform to gain valuable insights and translate them into potential therapeutic solutions.
With Valo’s preclinical capabilities, novel druggable targets can be identified and validated. Additionally, the company can develop drug candidates that specifically target these identified areas and assist in predicting compound safety and efficacy.
As part of the agreement, Novo Nordisk will license three preclinical drug discovery programs in cardiovascular diseases that were discovered and developed by Valo. This includes their highly successful weight-loss drugs Ozempic and Wegovy.
Valo will receive an upfront payment and a potential near-term milestone payment totaling $60 million. They are also eligible for milestone payments of up to $2.7 billion, along with research and development funding and potential royalty payments.
The collaboration between Novo Nordisk and Valo Health signifies a promising step forward in addressing critical cardiometabolic diseases. By harnessing the power of human data and AI, they aim to generate groundbreaking treatments that can make a substantial difference in patients’ lives.